These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32458310)

  • 21. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
    Zhang YP; Wu WZ; Cui GX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1341-4. PubMed ID: 25338585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
    Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
    Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
    Hong M; Zhu H; Sun Q; Zhu Y; Miao Y; Yang H; Qiu HR; Li JY; Qian SX
    Aging (Albany NY); 2020 Apr; 12(7):5792-5811. PubMed ID: 32238611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014).
    Zhang Y; Li X; Weng X; Shen Y; Chen Y; Zheng Y; Zhao H; You J; Mao Y; Wang L; Wu M; Sheng Y; Wu J; Hu J; Chen Q; Li J
    Am J Hematol; 2022 Jan; 97(1):43-51. PubMed ID: 34687467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
    Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D
    Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease may be an early prognostic indicator for newly diagnosed acute myeloid leukemia patients induced by decitabine-based chemotherapy.
    Tan Y; Fu Y; Liu C; Sun J; Liu S; Lin H; Liu Q; Yang Y; Li Y; Su L; Gao S
    Hematology; 2019 Dec; 24(1):552-558. PubMed ID: 31315553
    [No Abstract]   [Full Text] [Related]  

  • 28. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
    Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
    Sun Y; Xu Y; Wu D; Shen H; Yang Z; Qiu H; Chen S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1025-30. PubMed ID: 26759106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
    Wang L; Luo J; Chen G; Fang M; Wei X; Li Y; Liu Z; Zhang Y; Gao S; Shen J; Wang X; Gao X; Zhou W; Ma Y; Liu H; Li X; Yang L; Sun K; Yu L
    Clin Epigenetics; 2020 Sep; 12(1):132. PubMed ID: 32873343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
    Yu W; Mao L; Qian J; Qian W; Meng H; Mai W; Tong H; Tong Y; Jin J
    Ann Hematol; 2013 Aug; 92(8):1091-100. PubMed ID: 23595277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
    Takahashi W; Nakamura Y; Tadokoro J; Handa T; Arai H; Tokita K; Iso H; Tsurumi S; Sasaki K; Maki K; Mitani K
    Rinsho Ketsueki; 2012 Jan; 53(1):71-7. PubMed ID: 22374527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
    Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
    Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
    Wei G; Ni W; Chiao JW; Cai Z; Huang H; Liu D
    J Hematol Oncol; 2011 Nov; 4():46. PubMed ID: 22082134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia.
    Duan W; Yang S; Zhao T; Hu L; Qin Y; Jia J; Wang J; Lu S; Jiang H; Zhang X; Xu L; Wang Y; Lai Y; Shi H; Huang X; Jiang Q
    Ann Hematol; 2023 Oct; 102(10):2695-2705. PubMed ID: 37572135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
    Li J; Chen Y; Zhu Y; Zhou J; Xu Y; Li Y; Yu K; Pan L; Wang J; Ding J; Gu J; Zhou S; Shi J; Hong M; Xu J; Pan L; Duan L; Zhang R; Zhang S; Zhu H; Lu H; Liu P; Qiu H; Wu H; Qian S
    Oncotarget; 2015 Mar; 6(8):6448-58. PubMed ID: 25749041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
    Fan C; Yu W; Mai W; Meng H; Qian W; Tong H; Huang J; Mao L; Suo S; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):100-4. PubMed ID: 27014977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy Comparison of Different Salvage Treatment Regimens for Patients with Refractory/Relapsed Acute Myeloid Leukemia].
    Gao WH; Li HM; Yu JY; Zheng YL; Wu LH; Liu QG; Li JF; Liu CH; Hu YM; Xu N; Li SZ; Mi YC; Huang PP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):340-345. PubMed ID: 28446272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.